EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and activity study of heterocyclic derivatives as JAK inhibitors

Shukhrat Gaybullaev, MiaoMiao Shi, Deng Zang, Shan Yang, Jiale Yan, Sardor Shakarov, Yuldash Takhirov, Davron Turgunov, Liyin Jiang, Jiangyu Zhao, Khurshed Bozorov, Chao Niu

Medicinal Chemistry Research · 2026-06 · 35 (6) · 1141-1160

DOI: 10.1007/s00044-026-03571-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicinal Chemistry Research, online erschienen am 26.05.2026. Verfasst von Shukhrat Gaybullaev und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Synthesis and Bioorganic Chemistry, Institute of Biochemistry, Samarkand State University, University Blvd. 15, Samarkand, 1401…. Hauptthemen laut MEDLINE: Drug Design, Heterocyclic Compounds, Quinazolines, Janus Kinase Inhibitors. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Tianchi Innovation Leading Talent Program, Natural Science Foundation of China, West Light Foundation, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Janus kinase (JAK) family plays a central role in regulating inflammation and fibrosis through the JAK/STAT signaling pathway, making it an attractive therapeutic target for immune-mediated diseases. In the present study, structural modifications of the quinazoline core were systematically explored to identify potent JAK inhibitors. A CXCL10-based screening strategy identified compound 22a as a promising lead, exhibiting strong inhibitory activity in HaCaT cells with an IC50 value of 308 nM. Subsequent kinase assays demonstrated that compound 22a exhibits higher inhibitory potency toward JAK1 (IC50 = 37.86 nM) compared to JAK2 (IC50 = 102.5 nM), JAK3 (IC50 = 69.35 nM), and TYK2 (IC50 = 2142 nM). Mechanistic studies revealed a dose-dependent suppression of STAT1 phosphorylation, confirming inhibition of the JAK1/2-STAT1 signaling pathway. In addition, molecular docking and molecular dynamics simulations were performed to elucidate and validate the binding mode of compound 22a within the JAK1 active site. Collectively, these results indicate that the developed quinazoline derivatives represent promising leads for the further development of selective JAK1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignHeterocyclic CompoundsQuinazolinesJanus Kinase InhibitorsProtein Kinase InhibitorsJanus KinasesHumansMolecular Docking SimulationStructure-Activity RelationshipJanus Kinase 1Cell LineMolecular StructureMolecular Dynamics SimulationJanus Kinase 3Dose-Response Relationship, DrugSignal TransductionTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

JAK inhibitorsMolecular dockingQuinazolinesSynthesisVitiligo

Substanzen

Heterocyclic CompoundsQuinazolinesJanus Kinase InhibitorsJanus Kinase 1Protein Kinase InhibitorsJanus Kinase 3Tyrosine Kinase InhibitorsJanus Kinases

Autor:innen und Institutionen

  • Department of Organic Synthesis and Bioorganic Chemistry, Institute of Biochemistry, Samarkand State University, University Blvd. 15, Samarkand, 140104, Uzbekistan.
  • State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, CAS Key Laboratory of Chemistry of Plant Resources in Arid Regions, Xinjiang Technical Institute of Physics and Chemistry, Chinese…
  • University of Chinese Academy of Sciences, 100049, Beijing, China.
  • Department of Chemistry, Urgench State University named after Abu Rayhan Biruni, 220100, Urgench, Uzbekistan.
  • University of Chinese Academy of Sciences, 100049, Beijing, China. zhaojy@ms.xjb.ac.cn.
  • Department of Organic Synthesis and Bioorganic Chemistry, Institute of Biochemistry, Samarkand State University, University Blvd. 15, Samarkand, 140104, Uzbekistan. khurshedbek@gmail.com.

Förderung

  • Tianchi Innovation Leading Talent Program
  • Natural Science Foundation of China
  • West Light Foundation, Chinese Academy of Sciences
  • Xinjiang International Science & Technology Cooperation Key Program
  • The Talent Project of Tianchi Young Doctoral Program in Xinjiang Uygur Autonomous
  • The CAS Pioneer Hundred Talents Program

Zitieren

APA

Gaybullaev, S., Shi, M., Zang, D., Yang, S., Yan, J., Shakarov, S., Takhirov, Y., Turgunov, D., Jiang, L., Zhao, J., Bozorov, K., & Niu, C. (2026). Design, synthesis, and activity study of heterocyclic derivatives as JAK inhibitors. Medicinal Chemistry Research, 35(6), 1141-1160. https://doi.org/10.1007/s00044-026-03571-0

Vancouver

Gaybullaev S, Shi M, Zang D, Yang S, Yan J, Shakarov S, et al. Design, synthesis, and activity study of heterocyclic derivatives as JAK inhibitors. Medicinal Chemistry Research. 2026;35(6):1141-1160. doi:10.1007/s00044-026-03571-0

BibTeX
@article{Gaybullaev2026,
  author = {Gaybullaev, Shukhrat and Shi, MiaoMiao and Zang, Deng and Yang, Shan and Yan, Jiale and Shakarov, Sardor and Takhirov, Yuldash and Turgunov, Davron and Jiang, Liyin and Zhao, Jiangyu and Bozorov, Khurshed and Niu, Chao},
  title = {Design, synthesis, and activity study of heterocyclic derivatives as JAK inhibitors},
  journal = {Medicinal Chemistry Research},
  year = {2026},
  volume = {35},
  number = {6},
  pages = {1141--1160},
  doi = {10.1007/s00044-026-03571-0}
}
Kostenlos starten →